Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 460 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: ALS - Amyotrophic Lateral Sclerosis Clear all

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Exercise; Procedure
Lead sponsor: University of Saskatchewan; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Not listed
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2040
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Amyotrophic Lateral Sclerosis, GI Cancer, Pancreatic Cancer
Interventions: TAILORED Patient Family Decision Making, standard of care; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 431 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Spinal Cord Injuries, Multiple Sclerosis, Transverse Myelitis, Amyotrophic Lateral Sclerosis
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Obstructive Sleep Apnea, Amyotrophic Lateral Sclerosis, Muscular Dystrophies, Healthy
Interventions: Transmembrane EMG Oropharynx Probe; Device
Lead sponsor: Powell Mansfield Inc.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Amyotrophic Lateral Sclerosis
Interventions: prosetin, placebo; Drug
Lead sponsor: ProJenX; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • San Antonio, Texas

Conditions: Amyotrophic Lateral Sclerosis
Interventions: NurOwn (MSC-NTF cells); Biological
Lead sponsor: Brainstorm-Cell Therapeutics; Industry
Eligibility: 18 Years to 63 Years
U.S. locations: 5
States / cities: Irvine, California • San Francisco, California • Boston, Massachusetts + 2 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: MRI(magnetic resonance imaging); Diagnostic Test
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions: carbidopa-levodopa, Placebo Oral Tablet; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Amyotrophic Lateral Sclerosis
Interventions: DNL343, Placebo; Drug
Lead sponsor: Denali Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Scottsdale, Arizona • San Diego, California • San Francisco, California + 3 more

Conditions: Amyotrophic Lateral Sclerosis, Parkinson Disease, Dysphagia
Interventions: Videofluoroscopic Swallowing Examination, Tongue Strength Measurement; Diagnostic Test · Other
Lead sponsor: University Health Network, Toronto; Other
Eligibility: 18 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Sleep study-guided adjustment of NIV, Standard initiation of NIV; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Amyotrophic Lateral Sclerosis, Progressive Muscular Atrophy, Motor Neuron Disease
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 25 participants
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: ALS
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 13
States / cities: Los Angeles, California • Aurora, Colorado • Ann Arbor, Michigan + 10 more

Conditions: Neurodegenerative Disease, Weight Loss, Amyotrophic Lateral Sclerosis, Parkinson's Disease, Huntington's Disease, Cachexia
Interventions: In-Person Nutritional Counseling by a Registered Dietitian, Nutritional counseling using an e-Health Application; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Primary Lateral Sclerosis, Hereditary Spastic Paraplegia, Progressive Muscular Atrophy, Multisystem Proteinopathy
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: Not listed
Enrollment: 708 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2031
U.S. locations: 13
States / cities: Palo Alto, California • San Diego, California • San Francisco, California + 10 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: dextromethorphan HBr and quinidine sulfate; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 2
States / cities: Fort Lauderdale, Florida • Gainesville, Florida

Conditions: Amyotrophic Lateral Sclerosis
Interventions: KetoCal; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS
Interventions: Foralumab Nasal, Placebo; Drug
Lead sponsor: Tiziana Life Sciences LTD; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Davie, Florida • Chicago, Illinois • Boston, Massachusetts + 1 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions: Not listed
Lead sponsor: University of Alberta; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 2
States / cities: Miami, Florida • Salt Lake City, Utah

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Ezogabine, Placebo; Drug
Lead sponsor: Brian Wainger; Other
Eligibility: 18 Years to 80 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 12
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 8 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg); Drug
Lead sponsor: PhenoNet, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more

Conditions: C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 7
States / cities: Los Angeles, California • Baltimore, Maryland • Amherst, Massachusetts + 4 more

Search by objective public record fields.

Study of the Effects Strengthening Exercises in Individuals With ALS

The National Amyotrophic Lateral Sclerosis Registry

Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life

AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis

Transmembrane Electromyography (TM-EMG) for the Assessment of Neuromuscular Function in the Oropharynx

A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS

Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS

Developing a Discrimination Model to Diagnose ALS

Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis

A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis

Physiological Flow of Liquids Used in Dysphagia Management (Neuro)

Polysomnography-directed Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)

Study of ALS Reversals 4: LifeTime Exposures

Genomic Translation for Amyotrophic Lateral Sclerosis Care

Electronic-health Application To Measure Outcomes REmotely Clinical Trial

Phenotype, Genotype & Biomarkers in ALS and Related Disorders

Impact of Nuedexta on Bulbar Physiology and Function in ALS

Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS)

The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab

DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS

Novel MRI Biomarkers for Monitoring Disease Progression in ALS

Clinical Trial of Ezogabine (Retigabine) in ALS Subjects

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS